	ICMJE DISCLOSURE FOI	RM
Date:	7/22/2024	
Your Name:	Arnold Bakker	
Manuscript Title:	The HOPE4MCI study: AGB101 treatment slo ApoE-4 non-carriers with mild cognitive imp	ows progression of entorhinal cortex atrophy in airment due to Alzheimer's disease
Manuscript Number (if k	nown): TRCI-D-24-00049	
content of your manuscriaffected by the content of indicate a bias. If you are The author's relationship epidemiology of hyperter that medication is not medicated.	rency, we ask you to disclose all relationships/activitie pt. "Related" means any relation with for-profit or no if the manuscript. Disclosure represents a commitment in doubt about whether to list a relationship/activity/ss/activities/interests should be defined broadly. For ension, you should declare all relationships with manufactorioned in the manuscript.  all support for the work reported in this manuscript with past 36 months.	et-for-profit third parties whose interests may be not to transparency and does not necessarily //interest, it is preferable that you do so.  Example, if your manuscript pertains to the acturers of antihypertensive medication, even if
	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	[□] None [R01AG061091	NIH Grant to Johns Hopkins University  Click the tab key to add additional rows.
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	AgeneBio, Inc.	Consultant
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Science Luncheon Series. UTD Center for Vital Longevity. Dallas, TX	Honorarium for invited lecture.
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
80	Patents planned, issued or pending	US-2021244709-A1 Methods and compositions for improving cognitive function	Listed inventor
9	Participation on a Data Safety Monitoring Board or Advisory Board	DSMB Member, NIH supported clinical trial: Network-Level Mechanisms for Preclinical Alzheimer's Disease Development (1R21AG056882). Medical College of Wisconsin, Milwaukee WI, USA.	Not compensated.
10	Leadership or fiduciary role in other board, society, committee or	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	advocacy group, paid or unpaid		
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea [⊠]	-	t to the following statement to indicate your agreeme answered every question and have not altered the wo	

3 12/13/2021 ICMJE Disclosure Form

## ICMJE DISCLOSURE FORM

Date:	7/22/2024
Your Name:	Nisha Rani
Manuscript Title:	The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in ApoE-4 non-carriers with mild cognitive impairment due to Alzheimer's disease
Manuscript Number (if known):	TRCI-D-24-00049

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	•	t to the following statement to indicate your agreeme	

## ICMJE DISCLOSURE FORM

Date: 22/July/2024	Date:22/July/2
our Name:Richard C Mohs	Your Name:Ric
Manuscript Title: The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex	Manuscript Title:_
trophy in ApoE-4 non-carriers with mild cognitive impairment due to Alzheimer's disease"	atrophy in ApoF
Manuscript number (if known): TRCI-D-24-00049	Manuscript number

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	
1	All support for the present	National Institute on Aging	Grant R01AG061091 "A Phase 3 Pivotal Trial
	manuscript (e.g., funding,		of AGB101 to Slow Progression in MCI due to
	provision of study materials,		Alzheimer's Disease"
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	PI for Grant R01AG061091 "A Phase 3 Pivotal Trial
	any entity (if not indicated	National Institute on	of AGB101 to Slow Progression in MCI due to
	in item #1 above).	Aging	Alzheimer's Disease"
3	Royalties or licenses	X_None	
4	Consulting fees	None	Global Alzheimer's Platform (GAP) Foundation;
			AgeneBio, Inc.

			Amyriad Therapeutics, Inc. MD Anderson Cancer Center
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert	X_None	MIS / MIGETSON CURICLE CENTER
0	testimony	XNone	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	Member, Board of Directors for Cogstate, Ltd.  Member, Board of Governors, Alzheimer's Drug Discovery Foundation
11	Stock or stock options	None	Holder of stock in Eli Lilly and Co.
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	_XNone	

Please place an "X" next to the following statement to indicate your agreement:

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## **ICMJE DISCLOSURE FORM**

Dat	e:	7/22/2024	
Υοι	ır Name:	Michela Gallagher	
Ma	nuscript Title:	-	ent slows progression of entorhinal cortex atrophy in ve impairment due to Alzheimer's disease
Ma	nuscript Number (if k	nown): _TRCI-D-24-00049	
cor affe	tent of your manuscrected by the content of	ipt. "Related" means any relation with for-profit	tivities/interests listed below that are related to the or not-for-profit third parties whose interests may be itment to transparency and does not necessarily tivity/interest, it is preferable that you do so.
epi	demiology of hyperte	os/activities/interests should be defined broadly. nsion, you should declare all relationships with n entioned in the manuscript.	For example, if your manuscript pertains to the anufacturers of antihypertensive medication, even if
	tem #1 below, report me for disclosure is th		ipt without time limit. For all other items, the time
		Name all entities with whom you have this relationship or indicate none (add rows as nee	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial pla	nning of the work
1	All support for the present manuscript (e.g.,	[ None	nning of the work
1	present manuscript (e.g., funding, provision	[—]	nning of the work
1	present manuscript (e.g., funding, provision of study materials,	[ None	Click the tab key to add additional rows.
1	present manuscript (e.g., funding, provision	[ None	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	[ None	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	[ None	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Phyllis F. Albstein Fund	Click the tab key to add additional rows.
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	[ None	Click the tab key to add additional rows.
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Phyllis F. Albstein Fund	Click the tab key to add additional rows.
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from	Phyllis F. Albstein Fund  Time frame: past 36 r	Click the tab key to add additional rows.
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Phyllis F. Albstein Fund  Time frame: past 36 r  □ None  P01AG009973	Click the tab key to add additional rows.  nonths  PI Michela Gallagher
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not	Phyllis F. Albstein Fund  Time frame: past 36 r	Click the tab key to add additional rows.  PI Michela Gallagher PI Richard Mohs (R01AG061091 site is one of
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item	Phyllis F. Albstein Fund  Time frame: past 36 r  □ None  P01AG009973	Click the tab key to add additional rows.  nonths  PI Michela Gallagher
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item	Phyllis F. Albstein Fund  Time frame: past 36 r  □ None  P01AG009973  R01AG061091	Click the tab key to add additional rows.  PI Michela Gallagher PI Richard Mohs (R01AG061091 site is one of the trial sites)

Institution (JHU)

licenses

US Patent Office

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	[□] None	
		AgeneBio, Inc.	self
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	See attached doc	Institutions
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid	[⊠] None	

	Stock or stock options	□ None		
		AgeneBio, Inc.	Self	
	Receipt of equipment, materials, drugs, medical writing, gifts, or other services	[⊠] None		
	Other financial or non-financial interests	[⊠] None		
Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

id	title	assignee
US-2021244709-A1	Methods and compositions for improving cognitive function	The Johns Hopkins University
US-10624875-B2	Methods and compositions for treating schizophrenia	The Johns Hopkins University
US-2022218665-A1	Methods and compositions for improving cognitive function	The Johns Hopkins University
US-2022265685-A1	Methods and compositions for improving cognitive function	The Johns Hopkins University
AU-2021200325-B2	Methods and compositions for improving cognitive function	The Johns Hopkins University
US-2008177061-A1	Target for therapy of cognitive impairment	Michela Gallagher, Pauline Kay Lund, Rothstein Jeffrey D
WO-2007019312-A3	Methods for characterizing and treating cognitive impairment i	r Univ Johns Hopkins, Michela Gallagher, Rebecca Haberman
BR-112017025031-B1	LEVETIRACETAM EXTENDED RELEASE PHARMACEUTICAL COMPO	S Agenebio, Inc
US-2014057903-A1	Methods for characterizing and treating cognitive impairment i	r The Johns Hopkins University
WO-2014144546-A1	Methods and compositons for improving cognitive function	The Johns Hopkins University
WO-2014078377-A1	Methods and compositions for treating schizophrenia	Agenebio, Inc.
WO-2010105189-A1	Method for identifying compounds that attenuate the function	The Johns Hopkins University
WO-2009139901-A2	Methods and compositions for improving cognitive function	The Johns Hopkins University
US-2005267076-A1	Method for improving cognitive function	Johns Hopkins University
WO-2006034485-A2	Treatment for age-related cognitive decline and other condition	n The Johns Hopkins University, University Of North Carolina
US-2006014801-A1	Prevention and treatment of cognitive impairment using (R)-(-)-	t The Johns Hopkins University
EP-3590506-A1	Extended release pharmaceutical compositions of levetiracetan	n Agenebio, Inc.
AU-2018208662-A1	Methods and Compositions for Treating Schizophrenia	The Johns Hopkins University
OA-18467-A	Extended release pharmaceutical compositions of levetiracetan	n Agenbio, Inc
WO-2014153180-A1	Methods and compositions for improving cognitive function	Michela Gallagher
AU-2013344646-A1	Methods and compositions for treating schizophrenia	The Johns Hopkins University
CA-3189302-A1	Combinations of gabaa alpha 5 agonists and sv2a inhibitors and	Agenebio, Inc., Michela Gallagher, Sharon Rosenzweig-Lipson